Skip to main content
Premium Trial:

Request an Annual Quote

Certis Oncology CertisAI Platform

Certis Oncology, a San Diego-based precision oncology and translational science company, has launched CertisAI, a predictive medicine platform that uses data, statistical algorithms, and multivariate machine learning to predict drug efficacy based on gene expression biomarkers. CertisAI can replace many traditional discovery screening studies with in silico predictions such as identifying biomarkers predictive of therapeutic response; uncovering biological pathway mechanisms of action; ranking cancer types most likely to respond to a lead candidate; and elucidating synergistic potential of combinatorial therapies. Researchers can also use the platform to select optimal cancer models for in vitro and in vivo validations studies, develop patient stratification strategies for clinical trials, and prioritize candidate in compound libraries and/or assess the value of intellectual property, the company said.

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.